个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共9条记录   ALMOREXANT Dual Orexin OX1/OX2 Antagonist Treatment of Sleep Disorders [作者：Owen, RT; Castaner, R; Bolos, J; Estivill, C,期刊：Drugs of the Future, 页码：5-10 , 文章类型： Article，,卷期：2009年34-1] Almorexant is a novel, selective, orally active dual orexin OX1 and OX2 receptor antagonist It is rapidly absorbed and distributed and shows no tendency to accumulate with repeated dosing Preclinical studies on rats and ... AMADACYCLINE Tetracycline Antibiotic [作者：Wang, Y; Castaner, R; Bolos, J; Estivill, C,期刊：Drugs of the Future, 页码：11-15 , 文章类型： Article，,卷期：2009年34-1] Amadacycline (PTK-0796) is an aminomethylcycline antibiotic with a broad spectrum of antibacterial activity The agent showed patent in vitro activity against multidrug-resistant and -susceptible Gram-positive e, Cram-neg... ISOFAGOMINE TARTRATE Glycogen Phosphorylase Inhibitor Treatment of Gaucher's Disease [作者：Dulsat, C; Mealy, N,期刊：Drugs of the Future, 页码：23-25 , 文章类型： Article，,卷期：2009年34-1] Isofagomine tartrate (AT-2101, HGT-3410, Plicera (TM)) is a new therapeutic candidate for the treatment of Gaucher's disease, the most common of the lysosomal storage syndromes, which is characterized by genetic mutation... GALGENPROSTUCEL-L/LITGENPROSTUCEL-L Prostate Cancer Vaccine [作者：Al-Kadhimi, Z; Heath, EI,期刊：Drugs of the Future, 页码：16-22 , 文章类型： Article，,卷期：2009年34-1] Prostate cancer is the second leading cause of cancer death in men in the United States Men with metastatic prostate cancer are treated initially with androgen deprivation therapy, and upon developing castrate-resistant ... OVERCOMING MULTIDRUG RESISTANCE IN CANCER: AN UPDATE ON RESEARCH OF NATURAL PRODUCTS [作者：Sun, LR; Cui, SX; Qu, XJ,期刊：Drugs of the Future, 页码：53-59 , 文章类型： Review，,卷期：2009年34-1] Multidrug resistance (MDR) in cancer cells con lead to chemotherapeutic failure The lock of effective therapies has created a growing need for developing new and effective chemotherapeutic agents to reverse MDR Recently,... CURRENT STATUS AND FUTURE DIRECTIONS IN ANTIPLATELET THERAPY [作者：Krakat, J; Mousa, S; Root, R; Mousa, SS,期刊：Drugs of the Future, 页码：27-41 , 文章类型： Review，,卷期：2009年34-1] Platelets are the principal effectors of cellular hemostasis and key mediators in the pathogenesis of thrombosis A variety of membrane receptors determine platelet reactivity with numerous agonists and adhesive proteins,... NUCLEOSIDE-BASED ADENOSINE A(3) RECEPTOR ANTAGONISTS AS DRUG CANDIDATES [作者：Tosh, DK; Jacobson, KA; Jeong, LS,期刊：Drugs of the Future, 页码：43-52 , 文章类型： Review，,卷期：2009年34-1] Purine nucleoside derivatives that are selective ligands for the A(3) adenosine receptor (AR) hove been structurally modified such that their ability to activate the receptor is lost while retaining high binding affinity... THERAPEUTIC TARGETS FOR ACUTE MYELOID LEUKEMIA (AML) [作者：Sorbera, LA; Verges, C; Dulsat, C,期刊：Drugs of the Future, 页码：67-77 , 文章类型： Article，,卷期：2009年34-1] Acute myeloid leukemia (AML) is a cancer of the myeloid line of white blood cells and is characterized by the hyperproliferation of abnormal cells, which collect in the bone marrow and disrupt normal blood cell productio... DRAVET SYNDROME (SEVERE MYOCLONIC EPILEPSY OF INFANCY) [作者：Pahlavan, G,期刊：Drugs of the Future, 页码：61-65 , 文章类型： Article，,卷期：2009年34-1] Dravet syndrome, or severe myoclonic epilepsy of infancy (SMEI), is an intractable epileptic encephalopathy first described by Dravet in 7978 It Its characterized by fever-sensitive and refractory generalized clonic, ton...